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Abstract 
Modelling and simulation has been used in many ways when developing new treatments. To 
be useful and credible, it is generally agreed that modelling and simulation should be 
undertaken according to some kind of Best Practice. A number of authors have suggested 
elements required for Best Practice in modelling and simulation. Elements that have been 
suggested include the pre-specification of goals, assumptions, methods and outputs. 
However, a project that involves modelling and simulation could be simple or complex; and 
could be of relatively low or high importance to the project. It has been argued that the level 
of detail and the strictness of pre-specification should be allowed to vary, depending on the 
complexity and importance of the project. This Best Practice document describes the 
elements required for the specification of a project, and requires that the practitioner justify in 
the specification the omission of any of the elements and, in addition, justify the level of 
detail provided about each element. This document is an initiative of the Special Interest 
Group (SIG) for Modelling and Simulation. The SIG for Modelling and Simulation is a body 
open to members of Statisticians in the Pharmaceutical Industry (PSI) and the European 
Federation of Statisticians in the Pharmaceutical Industry (EFSPI). Examples of a very 
detailed specification and a less detailed specification are included as appendices. 
Keywords: Modelling and simulation; Best practice; Monte Carlo technique; Pre-
specification, Quality control. 
1. Scope of this document 
We note that any project involving simulation has analytic elements, and involves model 
development, model selection and model checking. For purposes of this document, a project 
that involves modelling and simulation is one that has the objective of answering specified 
scientific or business questions using a statistical model or models, with the estimates from 
the model having a stochastic element; and/or having combinations of attributes that are not 
present together in a single dataset or in the individual assumptions used by the model; and/or 
extrapolating beyond the directly specified assumptions and/or beyond the support provided 
by the data on which the model is based. This Best Practice document applies to all projects 
that involve modelling and simulation as defined thus. See Table I for key definitions. 
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Rather than attempting to prescribe the content of inputs, methods and outputs pertaining to 
best practice, this document enumerates the required elements of a specification, and for best 
practice requires that the specification justify the level of detail and stringency of each 
element specified.  
-Table I about here- 
The document does not cover the details of investigative PK/PD modelling, but is designed to 
be generally applicable to modelling and simulation as used in any way in the development of 
new clinical treatments; it addresses the need for pre-specification in model informed clinical 
trial design and simulation. As part of best practice this document gives points to consider 
when deciding whether or not to use simulation.  
2. Objective of this document 
The objective of this document is to foster best practice in projects involving modelling and 
simulation. The document encourages appropriate use of modelling and simulation by 
describing the settings where simulation may and may not be useful; then the document 
proposes key elements of modelling and simulation that should be specified in advance.  
 The role of the specification 
The specification for a project involving modelling and simulation should be reviewed by 
team members, including those who will make use of the results of the project. Appropriate 
specification is necessary for best practice for a number of reasons. Firstly, a specification 
allows those who will make use of results to judge in advance whether in fact those results 
will help to answer the research question, and to contribute to improving the plan so as to 
answer the research question better. Secondly, when the project team uses an appropriate 
specification, the team will be enabled to act consistently to provide the planned outputs. 
Thirdly, if a project is adequately described in a specification, the degree to which the project 
achieved its specified goals can be assessed and the results reproduced. Thus appropriate 
specification encourages best practice in communication, planning and evaluation of the 
modelling-and-simulation project. 
It is recognized that the level of stringency with which a project is specified, carried out and 
checked should take into account the importance of that project. For example, at the 
European Medicines Agency-European Federation of Pharmaceutical Industries and 
Associations (EMA-EFPIA) Modelling and Simulation Workshop in 2011 it was “agreed that 
different standards will apply depending on the impact of M(odelling )&S(imulation).” [1]; 
and an EMA speaker noted that there should be “Different standards for different exercises 
(L(ow) M(edium) H(igh importance))” [2]. Projects that involve modelling and simulation 
thus vary widely with regard to the level of detailed pre-specification and the level of quality 
control that can be justified as Best Practice. While this document does not prescribe the 
contents of elements of the specification in detail, in some cases it provides suggestions. 
Appendices containing examples of specifications for projects requiring low and 
medium/high levels of stringency are available as separate documents. 
In reality, deviations from the specification may occur while undertaking a project. 
Furthermore, projects that involve modelling and simulation are often iterative. That is, a first 
run of the simulation and analysis often gives rise to questions that can be well answered by a 
re-run of the modelling and simulation, with amendments to the specification. With 
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appropriate recording of deviations and amendments, the impact of these is auditable and can 
be assessed (see Section 3.4 “Quality Control” and Section 4 “Changes to the specification”).  
3. Introduction 
Modelling and simulation uses rules derived from the observation of existing conditions in 
new but related conditions. Modelling and simulation allows the analyst to interrogate the 
interaction between one or more models and new assumptions. Modelling and simulation can 
be used in many ways when developing a treatment, from drug discovery to health 
technology assessment. In the simplest case, modelling and simulation could provide 
predictions from a well specified model, under a new set of conditions. At its most complex, 
modelling and simulation could use a variety of models, methodologies, and inferences, 
and/or require assumptions for situations that have not yet been observed or that can be 
derived only indirectly from observed data. The risk of the methods used may be 
commensurate with the differences vis-à-vis the previously observed conditions, and with the 
complexity of the modelling and simulation. The reporting of such studies should 
communicate this clearly. 
Modelling and simulation typically involves applying model-based mathematical/statistical 
results that can be used as evidence in drawing conclusions about the behaviour of specific 
project characteristics. 
A note on terminology: statistical models make use of assumptions, but model parameters 
tend to be estimated from real or historical data. Sometime we can use Bayesian prior 
parameters which can also be supported by historical information. If the project is developing 
over time, typically the estimates of model parameters are updated using interim data to 
update the posterior estimates. However, in projects involving modelling and simulation, 
there is in practice great flexibility in the degree to which the model is derived from a mixture 
of assumptions and of data. Sometimes, the values of parameters will be assumed, based 
loosely on historic data or on expert opinion. Therefore, this document tends to use the term 
“assumptions and data” where often the term “data” would be used. 
 Closed-form approaches vs. simulation 
In projects involving modelling and simulation, either closed-form solutions/mathematical 
formulae can be used (which are known or derived for the purposes of the projects), or use 
may be made of Monte Carlo simulation, or the results can be obtained by using a 
combination of both approaches. 
Typically each project involving modelling and simulation consists of several stages. In the 
first stage, models are defined that link the initial assumptions or input data to the outcome(s) 
that need to be analysed. The second part involves the process of generating outcomes which 
can be done either by applying closed-form solutions or by using Monte Carlo simulation. 
Then the results (outcomes) are analysed with the objective of testing particular hypotheses 
or proving the existence of specific properties. As usual this analysis is made using statistical 
tests based on analytic solutions, e.g. testing the equality of means.  
For some projects both closed-form analytic solutions and Monte Carlo simulation may be 
used. Typically, closed-form solutions can be derived for projects where we use standard 
types of distributions and outcome measures for which formulae are known, e.g. Gaussian or 
Poisson models without truncation. As usual, using closed-form expressions is preferred as 
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this reduces the time required for analysis and eliminates errors due to the simulation process 
itself (“stochastic variability”). However, for many projects it may be difficult to derive 
closed-form solutions. In these cases Monte Carlo simulation techniques are used, sometimes 
combining the results obtained by simulation using analytic techniques. 
Note that for some projects it might be appropriate instead of exact distributions to use 
approximations – often a normal or Poisson approximation. In the case of a normal 
approximation, it is enough to evaluate the mean and standard deviation (SD) of the resulting 
outcome, where in many cases the mean and SD can be calculated directly. In such cases the 
project may not require Monte Carlo simulation.       
Examples of a project with a model whose estimates have a stochastic element: 
 A project that simulates patient outcomes in order to assess the operating 
characteristics of candidate analysis methods.  
 A project that predicts future patient enrolment at interim time. 
An example of a project with estimates that have combinations of attributes that are not 
present in the data or individual assumptions used by the model: 
 A simulation of a dose-finding study with safety and efficacy profiles taken from 
separate sources for a range of doses, where both safety and efficacy must be taken 
into account together in assessing the risks and benefits of a design to identify viable 
doses of a new treatment.  
An example of a model that extrapolates beyond the assumptions or data: 
 A PK model that estimates serum concentrations for obese patients from those of non-
obese patients.  
Examples of projects that may allow closed-form solutions: 
 A project which requires the evaluation of the cumulative outcome where the 
individual outcome is the number of events during the exposure time, where the rate 
of events may depend on subject covariates. In this case, if the rates and exposure 
times are given, the cumulative outcome has a Poisson distribution, in which case 
Monte Carlo simulation is not required. 
 For a large number of subjects, it would be enough to evaluate the mean and SD of 
individual outcome. This can be done analytically only for some special cases, e.g. 
where the rates are known and exposure times are either known and have some 
specific type of distribution, e.g. uniform or gamma. In this case, it is also possible to 
use a normal approximation for cumulative outcome and avoid Monte Carlo 
simulation. 
 For some projects, the opportunity to use closed-form solutions may depend on the 
logistics of project design. For example, for modelling global patient enrolment where 
there are not restrictions on the number of patients in different centres/regions we can 
use mixed Poisson process models that typically allow closed-form solutions [3]. 
However, if there are caps on the number of recruited patients in some regions, then 
pg. 5 
 
analytic solutions become rather complicated and the natural way would be to use 
Monte Carlo simulation. 
We note that in some projects the derived analytic relations and/or hypotheses about the 
behaviour of particular characteristics may benefit from verification by using Monte 
Carlo simulation of a variety of scenarios and illustration of the results by plots and 
tables. There are many papers (see e.g., [3]) that use Monte Carlo simulation as the 
engine to test and verify the analytic results. 
  
4. The Project Specification 
Unless otherwise stated, a specification for a project involving modelling and simulation 
should have headings/subheadings corresponding to each of the headings/subheadings of this 
section, “The Project Specification” and its subsections. Thus this section constitutes a check 
list that can be used when drafting a specification for a project involving modelling and 
simulation. The Introduction of the specification, the Presentation of results and the Summary 
if included, should be understandable by non-statisticians, the audience for all other sections 
of the specification should be the statistical team (statisticians and statistical programmers). 
 Summary 
A summary may be included. If included, the summary should as a minimum state the 
objective of the project.  
 Introduction of the specification 
The introduction of the specification should describe the objective of the modelling and 
simulation and state how the objective is addressed by the modelling and simulation.  
To the extent required by the project, the introduction should describe the clinical and 
operational setup (e.g. study design, indication, visits, treatments, enrolment scenarios, 
expected time to complete study, as appropriate); and the metrics and criteria used to draw 
conclusions. 
In some cases, it may be possible to provide in the Introduction a justification for a level of 
detail covering all elements of the specification; otherwise, justification of the level of detail 
provided for each element, including the Introduction, will be required. 
 Simulation and analysis/design 
The description of the simulation, analysis and design will have a number of elements. The 
level of detail with which each element is described should be justified.  
The description of the simulation should allow the reader to understand how the simulation is 
planned to be carried out. At its most detailed, this section should allow the reader to 
reproduce the simulations.  
The elements of the “Simulation and analysis” section of a specification are now covered 
individually. 
4.3.1 Scenarios assumed and assumptions made 
To the extent required by the project, the following should be described: 
 the assumptions made and their basis; 
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 a justification of those assumptions; 
 the scenarios under these assumptions and their clinical significance. 
The level of detail with which these are described should be justified here, if this is not done 
elsewhere. 
Scenarios should cover likely assumptions but, depending on the importance of the project, 
should also cover less-likely assumptions, preferably including assumptions unfavourable to 
the sponsor of the project, insofar as this can be planned in advance. If applicable, the degree 
to which assumptions are favourable and unfavourable to the sponsor should be stated and 
this statement justified. Where applicable, consider including a scenario where the null 
hypothesis pertains. 
If prior distributions are assumed for parameters, these distributions should be justified. 
As well as scenarios (often specified in terms of assumptions about model parameters), other 
assumptions of the model should be stated and justified. The specification may include a plan 
or recommendation for actions to verify the appropriateness of the model(s) used – see e.g. 
[4] for a standard text on model checking.  
4.3.1.1 Sensitivity analyses 
The specification should plan for, describe and justify analyses that assess the sensitivity of 
the conclusions to the primary assumptions of the project, and should describe the output of 
these analyses. This may be done in the course of specifying the variety of scenarios in 
Section 3.3.1 “Scenarios assumed and assumptions made”. If no sensitivity analyses are 
performed, this omission should be justified. In particular, consider assessing sensitivity to 
missing data. An assessment of sensitivity to compliance may be considered. 
4.3.2 Datasets generated 
The process that generates the datasets should be described and the level of detail of this 
description justified. If suitable data could be simulated using bootstrap methods, it may be 
appropriate to provide justification for the use or non-use of bootstrap methods to generate 
the data sets. 
4.3.3 Statistical analysis 
The statistical analysis performed on the simulated datasets should be described and the level 
of detail of this description justified. 
4.3.4 Operating characteristics 
This section should describe the procedures used to calculate and justify estimated power to 
detect relevant differences in criteria used for conclusions. The section should also describe 
the assumptions made for this estimate of power and include description of the basis of those 
assumptions. If relevant to the objective of the project, this section should describe the 
procedures used to calculate type I error (probability of false positive finding for a null-
hypothesis scenario). If Monte Carlo simulation is used, the number of simulations should be 
justified and the simulation error should be estimated. Burton et al. [5] give useful formulae 
to help with these calculations. It is recognized that feasibility may be a factor in deciding on 
the power/number of simulations. 
The level of detail of the description of the operating characteristics should be justified.  
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4.3.5 Logistics 
Modelling and simulation can be affected by the parameters of the execution environment. 
Differences between hardware and operating systems can cause differences in absolute 
numeric values, which could be magnified using certain methods. The execution environment 
should be specified in sufficient detail to allow the results to be recreated. 
The modelling and simulation will be affected by the implementation of the code. The 
specification should name software tools used, and the version numbers of those tools. This 
includes version numbers for the coding environment (R, SAS, etc.), modules of add-in code, 
and user generated commands. 
The specification may include recommendations for optimising programming code with 
respect to speed, use of computer memory and/or development time  
If the code is not provided as an appendix/supplementary materials, the location of the code 
repository should be specified.  
Give details of the mechanism used for creating pseudo-random variables if this is not 
apparent from the description of the logistics. State the seeds to be used.  
The level of detail of the description of the logistics should be justified. 
If applicable, this section should describe contingency actions for foreseeable practical 
problems such as lack of convergence or clinically unrealistic simulated values, and should 
justify the level of detail used for this description. 
 
 Quality control 
As with other elements, the level of quality control (QC) for a project involving modelling 
and simulation may vary depending on the importance of a project. Projects are often 
categorised as of low, medium or high importance. An example of a project of low 
importance could be a simulation that is used to verify a known formula. An example of a 
project of medium importance could be where conventional analyses produce valid results 
but simulation is used to provide additional summaries that are easier to interpret clinically – 
no new conclusions may be drawn from the results of the simulation, but the simulation 
results will contribute to the decision-making process. An example of a project of high 
importance could be where results from modelling and simulation are used in a regulatory 
submission to support a use of a new treatment, for a subgroup of patients not directly 
assessed in a randomized clinical trial. 
For projects of low importance, the specification should be reviewed independently. Software 
tools used for generating results may be software accepted.  
For projects of medium importance, the specification should be reviewed independently. 
Software tools used for generating results should be software accepted. It should be verified 
that under known conditions the analytical results display expected characteristics. In 
addition, the user code may be peer reviewed, and may be unit tested where appropriate to 
verify expected behaviour. 
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For projects of high importance, the specification should be reviewed independently. 
Software tools used for generating results should be software accepted. The user code should 
be peer reviewed. Unit testing may be used to verify expected behaviour. The project results 
should be quality controlled via independent programming. Independent programming is the 
comparison of the outputs from two independently programmed models/simulations that 
follow the same specification. This can be a reliable QC of both the correctness of the 
computer code and the clarity of the specification, both of which are sources of error in 
practice.  
Quality control of the generation of the data can be separated from QC of the analysis and 
presentation of results. The QC of the generation of the data could be performed via 
independent programming using a common seed and agreed outline of the order of the 
implementation of steps (including agreed order of sorting of data pertaining to the 
generation of the pseudo-random variables). 
The specification may require that programs and/or datasets be auditable. 
The QC strategy should be described in the specification. The specification should justify the 
level of planned QC. 
 Presentation of results 
The specification should describe the items planned to be estimated overall. The items 
planned to be estimated at each simulation should also be described, or the omission of this 
description justified. If there is a hierarchy of summaries, this should be described and the 
estimates pertaining to each level of the hierarchy described, or its omission justified. It is 
recognized that the presentation of results may vary depending upon the audience for the 
presentation. This section of the specification should describe how the results will be 
presented and justify the contents, format and level of detail of the presentation for each 
planned audience. Graphical presentations should be considered. 
This section should also describe how the bias, accuracy and coverage of the results will be 
presented, or justify the omission of these items from the presentation. 
Confidence intervals should be presented for results, or their omission justified. 
As appropriate, this section should describe the format for storage of the items estimated and 
justify the level of detail used for this description. 
5. Changes to the Specification 
The specification for a project that involves modelling and simulation should when finalised 
have a dated signature attached to it in an auditable fashion, or a justification for the omission 
of this should be given in the specification. The date associated with the first final version of 
the specification should at the latest be prior to the date of the first generation of simulated 
data used to provide project results. If the date is later, a justification of this should be 
included. 
As noted (section 1, “Scope of this document”), projects involving modelling and simulation 
tend to be iterative, and thus amendments to the specification are often necessary. At least for 
projects of medium and high importance, amendments to the specification made after the first 
signed dated final version should be clearly indicated as amendments. Such amendments 
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should be signed, dated and justified, or the omission of these particulars should itself be 
justified. The version number should reflect amendments. Among other ways of recording 
amendments the following may be considered: 
 revision history 
 formal amendment, giving reason for change (analogous to protocol amendment) 
 including changes or new versions of the specification  as appendices. 
Programs and/or datasets may be auditable (see Section 3.4 “Quality Control”). 
Project programs and/or outputs should be linked in an auditable manner to the version of the 
specification used, or the lack of such links should be justified in the section of the 
specification that specifies Quality Control. 
 
6. Acknowledgements 
This document is an initiative of the Special Interest Group (SIG) for Modelling and 
Simulation. The SIG for Modelling and Simulation is a body open to members of 
Statisticians in the Pharmaceutical Industry (PSI) and the European Federation of 
Statisticians in the Pharmaceutical Industry (EFSPI). The authors thank Jason Wang and 
other PSI members for their useful feedback on drafts of this document, with special thanks 
to Chris Jennison for his important contribution to the Modelling and Simulation SIG 
Hackathon (February 2015, London), an exercise involving about 15 PSI members that 
helped to improve the Best Practice document greatly. We also thank those who attended the 
Hackathon. A number of valuable papers have been published on best practice for projects 
that involve modelling and simulation. This document benefits from work by, among others, 
Bonate et al. [6], US Food and Drug Administration [7], Burton et al. [5], Gaydos et al. [8], 
Smith et al. [9] and Burman et al. [10]. See also Marshall et al. [11] on the work of EFPIA on 
Good Practices in Model Informed Drug Discovery and Development (MID3).  
The authors contributed to this paper as follows: Michael O’Kelly created the draft 
document; Vladimir Anisimov added Section 3.1 on closed form approaches vs. simulation; 
Chris Campbell added much of Sections 4.3.5, 4.4 and 5 on Logistics, Quality Control and 
Changes to the Specification. Sinéad Hamilton added the sample specification in the 
Appendix, entitled “Using simulated data to assess analyses of negative binomial outcomes 
with missing data”. All authors reviewed the final draft. Vladimir Anisimov was affiliated to 
Quintiles (UK) when he contributed to the paper. 
7. References 
1. European Medicines Agency. EFPIA-EMA Modelling and Simulation Workshop 
Report. EMA-EFPIA Modelling and Simulation Workshop, 30 Nov – 1 Dec 2011, 
London. Available at 
http://www.ema.europa.eu/docs/en_GB/document_library/Report/2012/05/WC50012
7118.pdf. Accessed 31 March 2016. 
2. Hemmings R. M&S good practices and next steps. EMA-EFPIA Modelling and 
Simulation Workshop, 30 Nov – 1 Dec 2011, London. Available at 
pg. 10 
 
https://www.youtube.com/watch?v=BSsaUmMuUAE&index=12&list=PL7K5dNgKn
awY96v4FlgjTwUFAgUCXrRmw. Accessed 31 March 2016. 
3. Anisimov VV, Fedorov VV. Modelling, prediction and adaptive adjustment of 
recruitment in multicentre trials. Statistics in Medicine 2007; 26: 4958–4975. 
4. Cook R, Weisberg S. Applied regression including computing and graphics. 
Chichester: John Wiley and Sons, 1999. 
5. Burton A, Altman D, Royston P, Holder R. The design of simulation studies in 
medical statistics. Statistics in medicine 2006; 25: 4279-4292. 
6. Bonate P, Gillespie W, Ludden T, Rubin DB, Stanski D. Simulation in drug 
development: good practices. In Draft publication of the Centre for Drug 
Development Science (CDDS), Holford NHG, Hale M, Ko H, Steimer J-L, Sheiner 
LB, Peck CC (eds). University of California: San Francisco; 1999; pp. 1–18. 
7. US Food and Drug Administration, Center for Drug Evaluation and Research, Center 
for Biologics Evaluation and Research. Guidance for industry: population 
pharmacokinetics. US Food and Drug Administration: Rockville, MD, 1999. 
8. Gaydos B, Anderson K, Berry D, Burnham N, Chuang-Stein C, Dudinak J, Fardipoor 
P, Gallo P, Givens S, Lowis R, Maca J, Pinheiro J, Pritchett Y, Krams M. Good 
practices for adaptive clinical trials. Drug Information Journal 2009; 43: 539–556. 
9. Smith M, Marshall A. Importance of protocols for simulation studies in clinical drug 
development. Statistical Methods in Medical Research 2010; 20: 613-622. 
10. Burman C-F, Wiklund S. Modelling and simulation in the pharmaceutical industry—
some reflections. Pharmaceutical Statistics 2011; 10: 508-516. 
11. Marshall S, Burghaus R, Cosson V, Cheung S, Chenel M, DellaPasqua O, Frey N, 
Hamren B, Harnisch L, Ivanow F, Kerbusch T, Lippert J, Milligan P, Rohou S, Staab 
A, Steimer J, Tornøe C, Visser S. Good Practices in Model-Informed Drug Discovery 
and Development (MID3): practice, application and documentation. CPT: 
Pharmacometrics & Systems Pharmacology 2016; Accepted Article, doi: 
10.1002/psp4.12049 
 
 
 
  
pg. 11 
 
Table I: Glossary and definitions 
Term Definition 
Modelling and 
simulation 
project 
Project to answer specified scientific and business questions using 
model(s) with estimates that: 
 have a stochastic element, and/or 
 have combinations of attributes that are not present together in a 
single dataset or in the individual assumptions used by the model, 
and/or  
 extrapolate beyond the directly specified assumptions and/or 
beyond the support provided by the data used by the model. 
Monte Carlo 
simulation 
Simulation that uses repeated random sampling to obtain results; the 
random sampling may be pseudo-random, implemented via a computer 
Project 
importance 
 the importance of the results of the project for internal decision 
making, 
 the importance of the contribution to regulatory approval of the 
evidence resulting from the project, 
 more generally, the scientific importance envisaged with regard to 
the results of the project. 
See Section 3.4 “Quality Control” for examples of levels of 
importance. 
Software 
acceptance 
The process of defining the scope of a software tool, and checking that 
the software meets that specification, with an appropriate thoroughness 
based on project importance: 
 ad hoc testing (medium) 
 software specification, manufacturer's installation 
qualification/operational qualification/performance qualification 
(IQOQPQ) procedure, and formal acceptance testing (high) 
Stochastic Having an inherently random element, and therefore not capable of 
having its value predicted exactly 
Unit testing Testing individual units of source code to determine whether they are 
fit for use 
 
